Dr. Hendrik Van Poppel & Dr. Joaquin Mateo

I'm Virgil Still and Always. Well, this week on English Radio Barcelona Blue Voices, we'd like to really delighted to welcome back a former guest on the show, Dr. Joaquín Mateo, group leader of Valdebron Institute of Oncology's Prostate Cancer Research Group and chair of the European Society for Medical Oncology. Additionally, we have a longtime friend and colleague joining us for the first time on the show, Professor Dr. Andrik. Van Papel, Chairman of the European Association of Urology's Policy Office and former Chairman of the Department of Urology for the University Hospital in Louisville, Belgium. Welcome to the show, men. Hello, and thank you, Virgil, for inviting me again. Well, it's good to have you back, Kim, and Hein, it's good to have you for the first time on the show. Thank you, Virgil. It's almost over 20 years that we met. Yeah, it is. It is. It's incredible. Glad to join Mateo, Kim, as well. You know that I was working in Barcelona in 1984 at Hospital Clinico Com. Professor Eminente, Professor José María Gilvermet. So it's good to be back in Barcelona. Personalized medicine only works if patients know which questions to ask. Would you both agree with that? I fully agree. I think it is essential maybe certainly in deciding on treatment of advanced disease. And Kim can talk more about it. But when it comes to early detection, I think the evidence is still not there. It's more some kind of diagnostic and diagnostic where the expense to use that in a population-based screening program for prostate cancer would be an enormous expense for our health systems. Certainly, there is a place, but will this be applicable, applied, available, and reimbursed? I'm not sure yet. Well, Kim, I throw it to you since really this is the area that you use a lot, but I kind of look at it on the other side. If we do a better job of identifying potentially lethal disease at an earlier stage, even though it might be costly, in the long run it's going to be cheaper than having to treat advanced stage disease. Correct, I totally agree and I also agree with what Professor Van Popel just said. I think that we are at a time where we have many more possibilities than we had before to study prostate cancer but also to treat prostate cancer and the increasing number of resources and possibilities also mean that decisions sometimes are more complex. So in my opinion anything that involves making patients more aware. Now, for decades men have heard about PSA tests and biopsies, but prostate cancer diagnosis has changed